<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898726</url>
  </required_header>
  <id_info>
    <org_study_id>ElGalaa</org_study_id>
    <nct_id>NCT03898726</nct_id>
  </id_info>
  <brief_title>Laparoscopic Versus Transvaginal Cuff Closure</brief_title>
  <official_title>Comparison Between Laparoscopic Versus Transvaginal Cuff Closure After Total Laparoscopic Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>El-Galaa Military Medical Complex</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>El-Galaa Military Medical Complex</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is still debatable whether that the transvaginal approach to vault closure or laparoscopic&#xD;
      suturing are associated with lower risks of vaginal cuff complications .&#xD;
&#xD;
      This study aims to compare the two approaches of closure of the vaginal cuff at the end of&#xD;
      total laparoscopic hysterectomy as regards the vaginal cuff complications .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the women will subject to:&#xD;
&#xD;
      Preoperative Assessment including:&#xD;
&#xD;
        -  Detailed history taking including age ,parity, medical ,surgical history .&#xD;
&#xD;
        -  Physical examination:&#xD;
&#xD;
             -  General examination including the body mass index .&#xD;
&#xD;
             -  Abdominal examination including presence of previous scars, uterine size , any&#xD;
                tenderness and presence of palpable masses .&#xD;
&#xD;
             -  Pelvic examination: including uterine size, any adnexal mass and tenderness .&#xD;
&#xD;
        -  Preoperative investigation:&#xD;
&#xD;
             -  A preoperative trans-vaginal ultra- sonography to assess the volume of the uterus,&#xD;
                gross uterine pathology and any adnexal pathology.&#xD;
&#xD;
             -  The preoperative laboratory investigation: hemoglobin percent and haematocrit&#xD;
                value, blood grouping ,liver and kidney function tests.&#xD;
&#xD;
      Availability of blood was ensured for each patient before surgery.&#xD;
&#xD;
      Anaesthesia:&#xD;
&#xD;
      Standardized general anaesthetic technique consisting of induction agent, muscle-relaxant and&#xD;
      inhalational agents with basic minimum monitoring after a detailed pre-anaesthetic check-up&#xD;
      and adequate premedication advice.&#xD;
&#xD;
      Intraoperative :&#xD;
&#xD;
        -  For vaginal cuff closure both in laparoscopic approach and vaginal route, the&#xD;
           investigators will use the horizontal method, which can be described as closing the&#xD;
           vagina anterior to posterior by leaving a horizontal scar. The repair will start at one&#xD;
           end of the vaginal cuff, and will continue toward the surgeon , using a continuous&#xD;
           Vicryl suture .&#xD;
&#xD;
        -  In the laparoscopic approach, needles will be introduced through one trocar and removed&#xD;
           through the opposite trocars using a needle holders.&#xD;
&#xD;
      Postoperative care:&#xD;
&#xD;
        1. The patient will receive IV fluids in the first 24hours (3litres).&#xD;
&#xD;
        2. Oral clear fluid intake will be started 8 hours after the operation.&#xD;
&#xD;
        3. Another dose of antibiotics will be received 6hrs after the operation with the same&#xD;
           regimen used in induction.&#xD;
&#xD;
        4. Postoperative analgesia will be received in the form of parental NSAIDs every 8hrs for&#xD;
           24hrs then on demand.&#xD;
&#xD;
        5. The urinary catheter and the vaginal pack will be removed 24hrs after the operation , no&#xD;
           drains will be left intraoperative.&#xD;
&#xD;
        6. CBC will be done 24hrs after the operation.&#xD;
&#xD;
        7. Histopathological examination of the specimen will be done.&#xD;
&#xD;
        8. Precocious resumption of coital activity ,( all patients will be recommended to avoid&#xD;
           vaginal intercourse for at least 2 months ) .&#xD;
&#xD;
      Follow Up:&#xD;
&#xD;
        -  Transvaginal ultrasound will be done to all patients in the second day to Spot vaginal&#xD;
           cuff hematoma if found .&#xD;
&#xD;
        -  Women will be discharged on antibiotic ( third generation cephalosporins ) and&#xD;
           analgesics ( NSAIDs ) and a follow-up visit will be scheduled after 7 days for a full&#xD;
           examination to exclude vaginal cuff infection ( purulent drainage from the vaginal cuff&#xD;
           on gross anatomic exam according to CDC ) or cuff hematoma (Any blood collection at the&#xD;
           level of vaginal vault detected by transvaginal ultrasound).&#xD;
&#xD;
        -  All women will be followed up after 3 months for the occurrence of vaginal cuff&#xD;
           dehiscence (separation of a vaginal incision that was previously closed at time of&#xD;
           initial hysterectomy) , at that time all women will undergo abdominal examination and&#xD;
           bimanual pelvic examination for vaginal masses.&#xD;
&#xD;
        -  All women will be asked for dyspareunia according to Marinoff scale:&#xD;
&#xD;
           0= no pain with intercourse .&#xD;
&#xD;
             1. pain with intercourse that doesn't prevent the completion .&#xD;
&#xD;
             2. pain with intercourse requiring interruption or discontinuance .&#xD;
&#xD;
             3. pain with intercourse preventing any intercourse .&#xD;
&#xD;
        -  Ethical Considerations:&#xD;
&#xD;
        -  Patient information and informed consent:&#xD;
&#xD;
      Before being admitted to the clinical study, the patient must consent to participate after&#xD;
      the nature, scope and possible consequences of the clinical study have been explained in a&#xD;
      form understandable to her.&#xD;
&#xD;
      Protocol approval:&#xD;
&#xD;
      Before the beginning of the study and in accordance with the local regulation followed, the&#xD;
      protocol and all the corresponding documents will be declared for Ethical and Research&#xD;
      approval by the council of the OB/GYN department, Ain Shams University.&#xD;
&#xD;
      Assessment of the outcomes:&#xD;
&#xD;
      Primary outcomes:&#xD;
&#xD;
      1. Vaginal cuff dehiscence: Any separation at the level of the vaginal vault.&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        1. Vaginal cuff hematoma:&#xD;
&#xD;
           Any blood collection at the level of vaginal vault detected by transvaginal ultrasound.&#xD;
&#xD;
        2. Post operative pelvic infections:&#xD;
&#xD;
           Any postoperative infection with signs and symptoms of vaginal cuff involvement&#xD;
           including granulation formation .&#xD;
&#xD;
        3. Operative time:&#xD;
&#xD;
           Time spent in suturing the vaginal cuff transvaginally versus laparoscopically .&#xD;
&#xD;
        4. Incidence of dyspareunia : according to Marinoff scale .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. number of cases ofVaginal cuff dehiscence</measure>
    <time_frame>3 months</time_frame>
    <description>Any separation at the level of the vaginal vault.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of cases with vaginal hematoma</measure>
    <time_frame>3 months</time_frame>
    <description>ultrasound finding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cases with vaginal infection</measure>
    <time_frame>3 months</time_frame>
    <description>purulent vaginal discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vaginal Cuff Dehiscence</condition>
  <condition>Vaginal Hematoma</condition>
  <condition>Vaginal Infection</condition>
  <arm_group>
    <arm_group_label>laparoscopical l cuff closure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>needle holder laparoscopic vaginal cuff closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>transvaginal cuff closure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>transvaginal cuff closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>laparoscopical l cuff closure</intervention_name>
    <description>closure of vaginal cuff following hysterectomy</description>
    <arm_group_label>laparoscopical l cuff closure</arm_group_label>
    <arm_group_label>transvaginal cuff closure</arm_group_label>
    <other_name>transvaginal cuff closure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients candidate for total laparoscopic hysterectomy :&#xD;
&#xD;
               -  Uterine size &lt;12 weeks.&#xD;
&#xD;
               -  Having no severe endometriosis.&#xD;
&#xD;
               -  Having descent of no more than 1st degree of uterus.&#xD;
&#xD;
               -  Non-malignant conditions.&#xD;
&#xD;
          2. Completion of the entire procedure by laparoscopic approach up to colpotomy.&#xD;
&#xD;
          3. Benign conditions as indications for hysterectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - 1) Obese patients i.e., BMI &gt; 30 k.g\m2. 2) Suspected extensive pelvic adhesions . 3)&#xD;
        Factors which may prolong wound healing as uncontrolled diabetes, ,prolonged corticosteroid&#xD;
        therapy ,advanced liver diseases.&#xD;
&#xD;
        4) Inability to express adequate informed consent to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>amr saad, MSC</last_name>
    <phone>01010051381</phone>
    <email>amrsaadobygyn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Saad</last_name>
    <phone>01113303665</phone>
    <email>ahmedsaad2910@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams university</name>
      <address>
        <city>Cairo</city>
        <zip>11111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>March 30, 2019</last_update_submitted>
  <last_update_submitted_qc>March 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>El-Galaa Military Medical Complex</investigator_affiliation>
    <investigator_full_name>amr saad mahmoud</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

